BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem - 2Iran war fuels fears of new inflation wave among German consumers
- 3Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- 4Winter storm warnings issued across Northeast as up to 9 inches of snow forecast; deadly atmospheric river in California snarls travel
- 5Trump signs a law returning whole milk to school lunches
- Collection of 7,000-year-old ostrich eggs discovered under sand dunes in southern Israel
- This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
- Massive supernova explosion may have created a binary black hole
- Empathy and reasoning aren’t rivals – new research shows they work together to drive people to help more
- Well known Worldwide Caf\u00e9s to Experience
- Role reversal: Ukraine moves training home and exports the lessons abroad
- Medtronic has 'significant firepower' for multiple acquisitions, executives say
- Volkswagen in talks with defence firms on use of Germany plant: CEO
- Deadly attack on kindergarten reported in Sudan
